Clinical trial
A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors
NCT00427349 is registered in ClinicalTrials.gov with Eastern Cooperative Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors
- Lead sponsor
- Eastern Cooperative Oncology Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 7, 2008
- Completion date
- April 30, 2015
- Enrollment
- 46 (actual)
- Sites
- 112
Conditions
As the registry lists them; a condition with its own page is linked.
gastrointestinal carcinoid tumor, islet cell tumor, neoplastic syndrome